On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
This table includes contact information for specialty pharmacies that provide Otezla. Specialty pharmacies may furnish patient support by providing:
You may send an Otezla prescription to one of these specialty pharmacies or to a pharmacy of your choice that is not listed here.
This table lists the insurance companies that currently cover Otezla. Amgen Inc. continually works to expand the number of insurance companies that cover the cost of Otezla. If a patient’s health plan isn’t on the list, please contact Amgen Inc. to inquire if additional plans have recently been added.
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Warnings and Precautions
Use in Specific Populations